RxDoctor Payments DataLook up a doctor →

Jonathon Chapman, MD

Gastroenterology · Baton Rouge, LANPI 1689867434

Payments from drug & device makers

$3,590,736in general payments, 2019–2025

Across 2,062 payments — averaging $1741.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1.3M
  • Takeda Pharmaceuticals U.S.A., Inc.$1.1M
  • Eli Lilly$284K
  • Janssen Research & Development, LLC$215K
  • Pfizer$194K
  • Bristol Myers Squibb$144K
  • plus $341K from 38 others
$18,330in research payments, 2019–2025

Across 4 payments — averaging $4582.51 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$18K

What the payments were for

  • Consulting fees$205,51421%
  • Speaking & faculty fees$646,10965%
  • Travel & lodging$115,71012%
  • Food & beverage$30,5293%
  • Education$3750%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,590,736 in reported general payments places this provider in the 95th percentile of 254 gastroenterology providers in Louisiana.

See all gastroenterology providers in Louisiana

Medicare billing

Part B allowed, 2024
$6,316
Medicare patients
36
Services billed
62

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab52$1,363,106
Skyrizi On-BodyRisankizumab-Rzaa38$750,975
Humira(Cf) PenAdalimumab30$390,785
RemicadeInfliximab16$124,967
RinvoqUpadacitinib15$121,702
ZeposiaOzanimod Hydrochloride13$112,134
Dupixent SyringeDupilumab14$91,744
ClenpiqSod Picosulf/Mag Ox/Citric Ac23$3,956
Colestipol Hcl27$2,374
Pantoprazole Sodium50$445
Omeprazole13$336
LoperamideLoperamide Hcl15$160

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara, Remicade$34,175$1,488,07368 claims
AbbVieRinvoq$1,272,456$121,70215 claims
E.r. Squibb & Sons, L.L.C.Zeposia$89,671$112,13413 claims
Ferring Pharmaceuticals Inc.Clenpiq$166$3,95623 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 254 gastroenterology providers in Louisiana.

Other gastroenterology in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →